HC Wainwright Analysts Decrease Earnings Estimates for DNTH

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share estimate for Dianthus Therapeutics to ($0.99), down from ($0.97), while maintaining a "Buy" rating with a price target of $40.00.
• The company reported a Q2 loss of ($0.88) EPS, missing the consensus estimate of ($0.86) and generating revenue of only $0.19 million, significantly below the expected $0.87 million.
• Despite recent downgrades, the consensus opinion from seven analysts remains a "Buy" with a price target averaging $53.00 per share for Dianthus Therapeutics.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2025 earnings estimates for Dianthus Therapeutics in a note issued to investors on Monday, August 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.99) for the quarter, down from their previous forecast of ($0.97). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics' Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.88) EPS, Q1 2026 earnings at ($1.07) EPS, Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($1.31) EPS, Q4 2026 earnings at ($1.34) EPS, FY2026 earnings at ($4.92) EPS, FY2027 earnings at ($4.51) EPS, FY2028 earnings at ($4.06) EPS and FY2029 earnings at ($0.96) EPS.

Other equities analysts have also issued research reports about the company. William Blair started coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They issued an "outperform" rating for the company. Robert W. Baird dropped their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Stock Up 2.4%

Shares of Dianthus Therapeutics stock traded up $0.49 on Wednesday, hitting $20.74. The stock had a trading volume of 280,117 shares, compared to its average volume of 337,294. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $32.27. The stock has a market cap of $667.62 million, a price-to-earnings ratio of -6.38 and a beta of 1.43. The stock's 50-day simple moving average is $19.49 and its two-hundred day simple moving average is $20.00.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. The company had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its holdings in shares of Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after acquiring an additional 3,317 shares during the period. Vestal Point Capital LP increased its stake in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after buying an additional 1,499,931 shares during the last quarter. Rafferty Asset Management LLC increased its stake in Dianthus Therapeutics by 19.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 28,522 shares of the company's stock valued at $531,000 after buying an additional 4,650 shares during the last quarter. Hudson Bay Capital Management LP raised its position in shares of Dianthus Therapeutics by 53.9% in the 2nd quarter. Hudson Bay Capital Management LP now owns 115,425 shares of the company's stock valued at $2,150,000 after buying an additional 40,425 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Dianthus Therapeutics by 3,547.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 49,531 shares of the company's stock valued at $923,000 after purchasing an additional 48,173 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.